As class action lawsuits go, I have never encountered one any more questionable than the recent complaint issued against Medivation Inc. (MDVN), via the law firm Izard Nobel LLP.

Readers of this space may recall that just a few days ago I decried the sell off of shares that occurred on the heels of Medivation's ill-fated phase 3 drug trial of the potential Alzheimer's treatment dimebon. At that time, I pointed out that one failed drug trial is not equal to the failure of a company. I still stand by that common sense determination.

I really wish I had several thousand dollars to play with right about now. If I did, I'd plunk the entire wad down on Medivation (MDVN) and let it ride.

Why would I do that? My reasoning is simple. I'd do that because the recent sell-off of Medivation, on the heels of a disappointing phase 3 study of the drug dimebon (latrepirdine) absolutely blew the floor out from under the company's shares. I'm telling you right now, I believe that sell-off has gone twice as deep as good sense can justify. At least, that's the way I see it.

Today's unemployment data coming in flat at 9.7%, and a lower than expected loss in non-Farm payrolls data, led the markets to treat the data as though there was really an add in jobs outside of weather. Stocks opened strong and stayed that way all day. If you can believe it, late day data from the Fed showed that Americans actually increased consumer credit in January. That is the first credit gain in a year, even if it is not universal.

Here were today's unofficial closing bell levels:

Dow 10,566.20 +122.06 (1.17%)
S&P 500 1,138.69 +15.72 (1.40%)
Nasdaq 2,326.35 +34.04 (1.48%)

For speculative investors aware of the risks associated with a development stage drug company, Karim Rahemtulla looks to Medivation (NASDAQ: MDVN), a play on development of a drug to treat Alzheimer's.

In his Xcelerated Profits Report, the advisor explains, "Medivation continues to make good clinical trial progress with its Dimebon drug for Alzheimer's Disease.

"The firm received some mainstream media attention at the recent International Conference on Alzheimer's Disease (ICAD) in Vienna. Reuters, Forbes and Bloomberg all reported that Dimebon is changing the way scientists think about Alzheimer's.

The highlight of the week, where all eyes will be focused (at least in the tech world), is the Apple Worldwide Developers Conference, which is all week long.

Monday June 11

• Apple Inc (NASDAQ: AAPL) Worldwide Developers Conference to be held from June 11 through June 15.
• Texas Instruments Incorporated (NYSE: TXN) mid-quarter update conference call to be held at 5pm.
• Medivation Inc (NASDAQ: MDVN) to discuss Phase II study results for Dimebon for Alzheimer's.

Tuesday June 12

• Lehman Brothers Holdings Inc (NYSE: LEH) to report Q2 earnings; conference call at 10am.

Wednesday June 13

• FDA Endocrinologic and Metabolic Drugs Advisory Committee Meeting on Sanofi-Aventis's (NYSE: SNY) Acomplia at 8am.

Thursday June 14

• The Goldman Sachs Group Inc (NYSE: GS) to report Q2 earnings; conference call at 11am.
• Adobe Systems Incorporated (NASDAQ: ADBE) to report Q2 earnings.
• Telkonet Inc (AMEX: TKO) to hold conference call at 11am to provide business update.

Friday June 15

• PDUFA date for Encysive Pharmaceuticals Inc's (NASDAQ: ENCY) Thelin for Pulmonary Arterial Hypertension (PAH).

MOST NOTEWORTHY: Nintendo Co, Ltd (NTDOY) and FuelCell Energy, Inc (FCEL) were the only noteworthy initiations in today's modest-sized list:

• JP Morgan started Nintendo Ltd (OTC: NTDOY) with an Overweight rating.
• Lazard initiated shares of FuelCell Energy (NASDAQ: FCEL) with a Buy rating and $11 target, as the firm believes the company has the best bookings prospects in its history.

OTHER INITIATIONS:

• Discovery Holding Co (NASDAQ: DISCA) was initiated at Pali Research with a Buy rating and $25.50 target. Pali said Discovery now appears committed to developing unique,"on-brand" proprietary content across all its cable networks that it can exploit through an increasing number of distribution platforms; Pali added that this is a company that no longer feels compelled to be in every country around the globe.
• Pacific Crest initiated shares of Vocus, Inc (NASDAQ: VOCS) with an Outperform rating and $28 target, as the firm believes the company has a strong competitive position.
• Cowen initiated Medivation, Inc (NASDAQ: MDVN) with a Neutral rating based on valuation.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).